ADVAMED COVID-19 DIAGNOSTIC SUPPLY REGISTRY

AdvaMed members manufacture and ship instruments and high-quality tests that, together with key inputs from our colleagues across the testing ecosystem (e.g., PPE, plastics, swabs, etc.), serve as the backbone of supply for the U.S. testing response to COVID.

AdvaMed has created a national COVID-19 Diagnostic Supply Registry to support state and federal governments in their pandemic responses. AdvaMed and its members are fully committed to providing key data to policymakers and the public in our collective work mobilizing against the pandemic.

AdvaMed is leading this data tracking and analysis effort, driven by thirteen leading diagnostic manufacturers whose tests together comprise ~75-80% of the COVID-19 Molecular IVD tests on the market in the U.S.

Key Data-Driven Summary of the U.S. COVID Testing Supply

Last updated June 11th, 2021

- Across leading COVID diagnostic manufacturers, ~**456 million** molecular COVID-19 tests have been shipped since March 2020, including **~357 million commercial tests** and **~99 million extraction reagents**.
- Per public sources, daily **Molecular tests run** decreased by 22% compared to the previous week, with an average of **~0.7 million**[2] tests per day last week.
- Registry participants collectively shipped **~2.8 million**[1] molecular tests for the week ending June 5th.
- High-quality **Serology testing** is widely available with industry **capacity to manufacture over 100 million tests per month.**
- Laboratory-based, and point-of-care **Antigen** testing – including over-the-counter home testing is widely available also with **manufacturing capacity for over 100 million tests per month**.

Weekly Molecular (MDx) tests shipped[3] & reported test results nationwide



1. Averaged over latest 4 weeks to account for fluctuations in purchase cycles. 2. Averaged over the week to account for fluctuations by day of the week. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests). 3. Weekly average over the last four weeks. 4. IVD and LDT molecular diagnostic test shipments. 5. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests). 6. The differential in tests shipped versus tests run is impacted by the inclusion of antigen data in the molecular tests run number, the share of test shipments that registry participants account for (75-80%) and pooling. When pooling is used, tests run is reported as 1 test per patient in the pool while tests shipped is reported as 1 test per pool.

AdvaMedDx

AdvaMed
Advanced Medical Technology Association